• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

    2/14/22 3:15:30 PM ET
    $PLXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLXP alert in real time by email
    SC 13G/A 1 plxpharma_13ga2.htm SC 13G/A
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    (Amendment No. 2)

    Under the Securities Exchange Act of 1934

    PLx Pharma Inc.

     

    (Name of Issuer)

    Common Shares

     

    (Title of Class of Securities)

    72942A107

     

    (CUSIP Number)

    December 31, 2021

     

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    o  Rule 13d-1(b)
    x  Rule 13d-1(c)
    o  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
             
    CUSIP No. 72942A107     13G/A   Page 2 of 8 Pages
             

    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    o
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER  
     
    0
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    0

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%1
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    CO
       
             

     

    1This percentage is calculated based upon 27,537,129 shares of the Issuer's common stock outstanding as of November 9th, 2021 in accordance with 10-Q filing.

     
     
             
    CUSIP No. 72942A107     13G/A   Page 3 of 8 Pages
             

    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    o
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    0

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%1
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
             

     

    1This percentage is calculated based upon 27,537,129 shares of the Issuer's common stock outstanding as of November 9th, 2021 in accordance with 10-Q filing.

     
     
             
    CUSIP No. 72942A107     13G/A   Page 4 of 8 Pages
             

    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    o
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    0

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%1
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    PN
       
             

     

    1This percentage is calculated based upon 27,537,129 shares of the Issuer's common stock outstanding as of November 9th, 2021 in accordance with 10-Q filing.

     
     
             
    CUSIP No. 72942A107     13G/A   Page 5 of 8 Pages
             

    Item 1.

      (a)

    Name of Issuer: PLx Pharma Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices
    9 Fishers Lane, Suite E

    Sparta, New Jersey

    07871 USA

         

    Item 2.

      (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF)

    Rosalind Master Fund L.P. (“RMF”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

    Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

         
      (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    175 Bloor Street East

    Suite 1316, North Tower

    Toronto, Ontario

    M4W 3R8 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    175 Bloor Street East

    Suite 1316, North Tower

    Toronto, Ontario

    M4W 3R8 Canada

         
      (c)

    Citizenship
    Rosalind Advisors, Inc.: Ontario, Canada

    Rosalind Master Fund L.P.: Cayman Islands

    Steven Salamon: Ontario, Canada

    Gilad Aharon: Ontario, Canada

         
      (d) Title of Class of Securities
    Common Stock
         
      (e) CUSIP Number
    72942A107
     
     
             
    CUSIP No. 72942A107   13G/A   Page 6 of 8 Pages
             

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)  

    Amount beneficially owned:   

    Rosalind Master Fund L.P. is the record owner of 0 shares of common stock.

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.

             
      (b)  

    Percent of class:  

    Rosalind Advisors, Inc. – 0%

    Rosalind Master Fund L.P. – 0%

    Steven Salamon – 0%

     
     
             
    CUSIP No. 72942A107   13G/A   Page 7 of 8 Pages
             
      (c)   Number of shares as to which the person has:  
           
          (i)

    Shared power to vote or to direct the vote  

     

    Rosalind Advisors, Inc. – 0

    Rosalind Master Fund L.P. – 0

    Steven Salamon – 0

    Gilad Aharon – 0

             
          (ii) Sole power to dispose or to direct the disposition of  – 0
             
          (iii)

    Shared power to dispose or to direct the disposition of  

     

    Rosalind Advisors, Inc. – 0

    Rosalind Master Fund L.P. – 0

    Steven Salamon – 0

    Gilad Aharon – 0

             

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     o.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable

     
     
             
    CUSIP No. 72942A107   13G/A   Page 8 of 8 Pages
             

    Item 10.  Certification.

          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
     

    2/14/2022

     

    Date

       
       /s/ Steven Salamon
     

    Signature

       
       Steven Salamon/President Rosalind Advisors, Inc.
     

    Name/Title

     

    Get the next $PLXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLXP

    DatePrice TargetRatingAnalyst
    12/7/2021$14.00Market Perform → Outperform
    Raymond James
    9/21/2021$29.00Buy
    BWS Financial
    More analyst ratings

    $PLXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

      SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the

      4/12/23 5:24:09 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Receives Nasdaq Delisting Notice

      SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na

      4/11/23 4:28:31 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PLx Pharma upgraded by Raymond James with a new price target

      Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00

      12/7/21 5:38:25 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BWS Financial initiated coverage on PLx Pharma with a new price target

      BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00

      9/21/21 8:29:27 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on PLx Pharma with a new price target

      Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00

      4/9/21 7:21:28 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Natasha bought $14,977 worth of shares (4,100 units at $3.65), increasing direct ownership by 378% to 5,186 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:35:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: O'Connor Rita M bought $50,122 worth of shares (13,700 units at $3.66), increasing direct ownership by 106% to 26,670 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:33:47 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Valentino Michael J

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      2/24/22 8:18:05 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLx Pharma Inc.

      SC 13G - PLx Pharma Inc. (0001497504) (Subject)

      4/6/23 9:15:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/14/23 1:38:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/16/22 6:15:38 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    SEC Filings

    See more
    • SEC Form 15-12G filed by PLx Pharma Inc.

      15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)

      10/18/23 4:01:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      9/20/23 4:39:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      8/22/23 5:24:50 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Financials

    Live finance-specific insights

    See more

    $PLXP
    Leadership Updates

    Live Leadership Updates

    See more
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

      SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi

      10/26/22 9:00:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

      - Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -

      8/12/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

      SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec

      1/19/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care